Keywords: Multiple sclerosis; Siponimod; Withdrawal; Rebound; Fingolimod;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Fingolimod; Lymphocytes; Multiple sclerosis; Relapses; Disability;
Keywords: Sphingosine kinase 1; Sphingosine-1-phosphate; Fingolimod; Pramipexole; Parkinson's disease;
Keywords: Fingolimod; Multiple sclerosis;
Keywords: Multiple sclerosis; Natalizumab; Fingolimod; Disease modifying drugs; Drug Switching; Immunomodulation; PE; primary endpoint; SE; secondary endpoint; REA; recurrent event analysis; PML; progressive multifocal leukoencephalopathy; aPBVC; annualized percent
Keywords: Multiple sclerosis; Alemtuzumab; Dimethyl fumarate; Fingolimod; Natalizumab; Teriflunomide; Adverse effects; Depression; Anxiety; Systematic review;
Keywords: ALS; amyotrophic lateral sclerosis; BDNF; brain-derived neurotropic factor; CerS; ceramide synthase; CNS; central nervous system; CPL; cecal ligation and puncture; cPLA2; cytosolic phospholipase A2; CSA; cyclosporine A; CTL; cytotoxic T lymphocytes; CYP45
Keywords: Multiple sclerosis; Fatigue; MS disease modifying treatment; Fingolimod;
Keywords: Multiple sclerosis; Fingolimod; Withdrawal, immune reconstitution inflammatory syndrome;
Keywords: DMT; disease modifying therapy; EDSS; Expanded Disability Status Scale; MRI; magnetic resonance imaging; MS; multiple sclerosis; Relapsing-remitting multiple sclerosis; Disease modifying therapy; Natalizumab; Fingolimod; Alemtuzumab; Systematic review;
Keywords: Tumefactive demyelinating lesion; Multiple sclerosis; Fingolimod; MRI;
Keywords: T lymphocytes; Blood-brain barrier; Intracerebral hemorrhage; Nude mice; Fingolimod;
Keywords: Dimethyl fumarate (PubChem CID: 637568); teriflunomide (PubChem CID: 54684141); fingolimod (PubChem CID: 107970); Glatiramer acetate (PubChem CID: 3081884); Multiple sclerosis; Dimethyl fumarate; Teriflunomide; Fingolimod; Immunogenetics;
Keywords: Multiple sclerosis (MS); Fingolimod; Neuroblastoma; Glioblastoma; S1P1 agonists; Molecular modeling studies;
Keywords: Evoked potential; Fingolimod; Multiple sclerosis; EDSS; VEP; SEP; MEP;
Keywords: Fingolimod; Heart rate; Heart rate variability; Multiple sclerosis;
Keywords: Fingolimod; Cryptococcal infection; Cryptococcal meningitis; Immunosenescence; Ms therapy; Cryptococcus;
Keywords: fingolimod; sphingosine-1-phosphate; macular edema; optic neuritis; multiple sclerosis; disease-modifying agents
Keywords: Dimethyl fumarate; Fingolimod; Comparative efficacy; Discontinuation; Multiple sclerosis
Keywords: multiple sclerosis; relapses; disease-modifying drugs; central nervous system; disability; magnetic resonance imaging; fingolimod; teriflunomide; dimethyl fumarate
Keywords: Relapsing-remitting multiple sclerosis; Focal damage; Diffuse damage; Brain volume loss; Fingolimod;
Keywords: Multiple sclerosis; Fingolimod; Cessation; Reactivation; Rebound
Keywords: Fingolimod; Multiple sclerosis; Clinical; Efficacy; Middle East; Lebanon
Keywords: LP; Lysophospholipid; LPA; lysophosphatidic acid; S1P; sphingosine 1-phospate; LPI; lysophosphatidylinositol; LysoPS; lysophosphatidylserine; LPC; lysophosphatidylcholine; LPE; lysophosphatidylethanolamine; LPG; lysophosphatidylglycerol; ATX; autotaxin; S
Keywords: AV; atrioventricular; AVB; atrioventricular block; ECG; electrocardiogram; FDA; US Food and Drug Administration; FDO; first-dose observation; FREEDOMS; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis; GIRK; G-protein-gated i
Keywords: Fingolimod; Glatiramer acetate; Interferon; Multiple sclerosis; Natalizumab; Prescribing; Utilisation
Keywords: Varicella zoster virus; Multiple sclerosis; Virus and multiple sclerosis; Fingolimod; Natalizumab;
Keywords: Fingolimod; Arrhythmia; Relapsing-Remitting Multiple Sclerosis; Atrio-ventricular block; Accelerated idioventricular rhythm Telemetry; Telemetry;
Lymphoprolifération cutanée primitive CD30+ sous fingolimod : un cas et revue systématique de la littérature
Keywords: Fingolimod; Lymphoprolifération cutanée primitive CD30+; Lymphome CD30+ anaplasique; Sclérose en plaques; Fingolimod; Primary cutaneous CD-30 positive cutaneous T-cell disorders; Relapsing-remitting multiple sclerosis;
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis
Keywords: Fingolimod; Meta-analysis; Multiple sclerosis; Real-world; Systematic literature review; Persistence;
Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod
Keywords: Multiple sclerosis; Fingolimod; Cutaneous large cell lymphoma; Side effect;
Drug toxicity profiling of a Saccharomyces cerevisiae deubiquitinase deletion panel shows that acetaminophen mimics tyrosine
Keywords: APAP; acetyl-para-aminophenol, acetaminophen; AMAP; acetyl-meta-aminophenol; CHX; cycloheximide; FTY720; fingolimod; HU; hydroxyurea; MMS; methyl methanesulfonate; Ubiquitin; Deubiquitinase; Toxicity; Tyrosine; Amino acids; Starvation; APAP;
Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases
Keywords: Tumefactive; Rebound; Fingolimod;
A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy
Keywords: Multiple Sclerosis; Pregnancy; Fingolimod;
Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab
Keywords: Multiple Sclerosis; Fingolimod; Alemtuzumab; Rebound;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
Fingolimod reduces the clinical expression of active demyelinating lesions in MS
Keywords: Fingolimod; Brain plasticity; MRI; Multiple sclerosis; Relapse; INFβ-1a;
Sphingolipids modulate docking, Ca2+ sensitivity and membrane fusion of native cortical vesicles
Keywords: α-NP; α-naphthyl-phosphate; CB; cerebrosides; DMS; dimethylsphingosine; FFM; fundamental fusion mechanism; Fin; fingolimod; PFM; physiological fusion machine; PMA; phorbol 12-myristate 13-acetate; Sph; sphingosine; S1P; sphingosine-1-phosphate; SphK; sp
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study
Keywords: AE; adverse event; ANCOVA; analysis of covariance; ARR; annualized relapse rate; CI; confidence interval; EDSS; Expanded Disability Status Scale; Gd+; gadolinium-enhancing; iDMT; injectable disease-modifying therapy; MRI; magnetic resonance imaging; MS; m
Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis
Keywords: Brain atrophy; Fingolimod; Experimental autoimmune encephalomyelitis (EAE); Magnetic resonance imaging (MRI);
Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase
Keywords: Sphingosine kinase 1; Sphingosine-1-phosphate; Fingolimod; Pramipexole; Parkinson's disease; MPTP;
Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis
Keywords: Multiple sclerosis; Choroidal thickness; Fingolimod;
Review articleClassifying PML risk with disease modifying therapies
Keywords: Disease modifying therapy; Multiple sclerosis; Progressive multifocal leukoencephalopathy; Natalizumab; Fingolimod; Dimethyl fumarate; Rituximab;
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients
Keywords: Multiple Sclerosis biomarkers; Immune system re-modulation; Fingolimod; Lymphocytes; Lymphocyte subsets;
Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view
Keywords: Multiple sclerosis; Fingolimod; Cerebral; Gray matter; Atrophy;
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch
Keywords: Biomarkers; Natalizumab; Fingolimod; Multiple sclerosis; Treatment change; Flow cytometry;
Application of Artificial Neural Networks in the Design and Optimization of a Nanoparticulate Fingolimod Delivery System Based on Biodegradable Poly(3-Hydroxybutyrate-Co-3-Hydroxyvalerate)
Keywords: artificial neural network; drug delivery; Fingolimod; poly(3-hydroxybutyrate-co-3-hydroxyvalerate); response surface methodology; training algorithms;
Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases
Keywords: Sphingosine1-phosphate receptors (S1PRs); FTY720; Fingolimod; Clinical trials; Fingolimod (PubChem CID: 107970); Siponimod (PubChem CID: 44599207); Ozanimod (PubChem CID: 52938427); Ceralifimod (PubChem CID: 11502996); Ponesimod (PubChem CID: 11363176);
Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial
Keywords: Multiple sclerosis; Fish oil; Fingolimod; Cytokines; Expanded disability status scale;
Fingolimod enhances myelin repair of hippocampus in pentylenetetrazol-induced kindling model
Keywords: Epilepsy; Demyelination; Fingolimod; Inflammation; Neuroprotection; Myelin protection;